Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APD421 (intravenous amisulpride) for treatment of established post-operative nausea and vomiting after prophylaxis
2015-003992-30Phase 3Completed
- Sponsor
- Acacia Pharma Group Plc
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amisulpride in postoperative nausea and vomiting (PONV) (3 arms), sponsored by Acacia Pharma Group Plc. Primary endpoint: Primary PONV treatment success. Started Dec 2015; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2015-003992-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003992-30.